Proof That Lower Is Better — LDL Cholesterol and IMPROVE-IT

The so-called LDL hypothesis is the concept that excess low-density lipoprotein (LDL) cholesterol is a causal factor in the development of atherosclerotic vascular disease. By extension, this hypothesis also assumes that reducing LDL cholesterol levels, regardless of the means, should produce a corr...

Full description

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 372; no. 25; pp. 2448 - 2450
Main Authors: Jarcho, John A, Keaney, John F
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 18.06.2015
Subjects:
Acute Coronary Syndrome - drug therapy
Anticholesteremic Agents - therapeutic use
Arteriosclerosis
Azetidines - therapeutic use
Cholesterol
Cholesterol, LDL - blood
Clinical trials
Female
Heart attacks
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Low density lipoprotein
Male
Simvastatin - therapeutic use
Statins
Systematic review
Vascular diseases
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The so-called LDL hypothesis is the concept that excess low-density lipoprotein (LDL) cholesterol is a causal factor in the development of atherosclerotic vascular disease. By extension, this hypothesis also assumes that reducing LDL cholesterol levels, regardless of the means, should produce a corresponding reduction in cardiovascular events. Considerable evidence supports the LDL hypothesis, including animal studies and epidemiologic studies involving humans, as well as clinical trials of both statins and nonstatin lipid-modifying agents. In a meta-analysis that included more than 90,000 participants in 14 randomized trials of statins, the Cholesterol Treatment Trialists’ (CTT) collaborators found that, on average, a reduction . . .
Bibliography:SourceType-Scholarly Journals-1
content type line 14
ObjectType-Editorial-2
ObjectType-Commentary-1
content type line 23
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMe1507041